VRTX · News · 20260814N

Guidance and Outlook

VERTEX PHARMACEUTICALS INC / MA · 2026-08-14 · Importance 75 · Surprise 60

Vertex raised its full-year 2026 revenue guidance to US$13.1 billion to US$13.2 billion. The updated outlook is above the materiality threshold of 3% of total revenue. Third-party commentary attributes longer-term growth potential to pipeline diversification across pain, kidney, and type 1 diabetes therapies, including genomic and gene-editing technologies.